Pub. Date : 2003 May
PMID : 14610915
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | With the cloning of the P2Y12 receptor, the molecular basis for ADP-induced platelet aggregation is seemingly complete. | Adenosine Diphosphate | purinergic receptor P2Y12 | Homo sapiens |
| 2 | P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). | Thienopyridines | purinergic receptor P2Y12 | Homo sapiens |
| 3 | P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). | Ticlopidine | purinergic receptor P2Y12 | Homo sapiens |
| 4 | P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). | Ticlopidine | purinergic receptor P2Y12 | Homo sapiens |
| 5 | P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). | Clopidogrel | purinergic receptor P2Y12 | Homo sapiens |
| 6 | P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo). | Clopidogrel | purinergic receptor P2Y12 | Homo sapiens |